Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Laura H. Porter"'
Autor:
Gail P. Risbridger, Ashlee K. Clark, Laura H. Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L. Lister, David Pook, Carmel J. Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B. Madsen, Hong Wang, Michelle G. Richards, Birunthi Niranjan, Samantha O’Dea, Linda Teng, William Wheelahan, Zhuoer Li, Nicholas Choo, John F. Ouyang, Heather Thorne, Lisa Devereux, Rodney J. Hicks, Shomik Sengupta, Laurence Harewood, Mahesh Iddawala, Arun A. Azad, Jeremy Goad, Jeremy Grummet, John Kourambas, Edmond M. Kwan, Daniel Moon, Declan G. Murphy, John Pedersen, David Clouston, Sam Norden, Andrew Ryan, Luc Furic, David L. Goode, Mark Frydenberg, Mitchell G. Lawrence, Renea A. Taylor
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
The prognosis of castration-resistant prostate cancers remains dismal, but accurate preclinical models can lead to effective therapies. Here the Melbourne Urological Research Alliance establish prostate cancer patient-derived xenografts, use the tumo
Externí odkaz:
https://doaj.org/article/72ce33db9321419ba5cb98782c40a1e1
Autor:
Luc Furic, Gail P. Risbridger, Renea A. Taylor, Kaylene J. Simpson, Ross D. Hannan, Richard B. Pearson, Elaine Sanij, David L. Goode, Andrew Bakshi, Jennii Luu, Susanne Ramm, Shahneen Sandhu, Carmel J. Pezaro, Jeremy P. Grummet, David Pook, Nicholas Choo, Laura H. Porter, Mitchell G. Lawrence
Supplementary Methods, Figures, and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::241fa416456af669f6859202417c09a5
https://doi.org/10.1158/1535-7163.22522815.v1
https://doi.org/10.1158/1535-7163.22522815.v1
Autor:
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clémentine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger
Publikováno v:
Nature Reviews. Urology, 20, 371-384
Nature Reviews. Urology, 20, 6, pp. 371-384
Nature Reviews. Urology, 20, 6, pp. 371-384
Item does not contain fulltext Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to study tumour biology and test therapeutics, linking the laboratory to the clinic. Although
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dff9e43370e7e5e999cf58ac4271e1d
http://hdl.handle.net/2066/293636
http://hdl.handle.net/2066/293636
Autor:
Melissa Papargiris, Natalie Lister, Hong Wang, Renea A. Taylor, Sam Norden, Shivakumar Keerthikumar, Andrew Ryan, Mahesh Iddawala, Michelle Richards, David L Goode, Mitchell G. Lawrence, Shomik Sengupta, Andrew Bakshi, Shahneen Sandhu, Jeremy Grummet, Laurence Harewood, John F. Ouyang, David Clouston, Heather Thorne, Luc Furic, Jeremy Goad, Rosalia Quezada Urban, Birunthi Niranjan, Nicholas Choo, Ashlee K. Clark, Carmel Pezaro, Samantha O'Dea, Daniel Moon, Declan G. Murphy, Lisa Devereux, Gail P. Risbridger, Jenna Kraska, Laura H Porter, Mark Frydenberg, Linda Teng, Rodney J. Hicks, Zhuoer Li, Heather B Madsen, David Pook, William Wheelahan, Arun Azad, John Pedersen, Roxanne Toivanen, John Kourambas, Edmond M. Kwan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications
Nature Communications
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collecti
Autor:
David Pook, Mural investigators, Andrew Bakshi, Ashlee K. Clark, Renea A. Taylor, David L Goode, David Clouston, John Kourambas, Gail P. Risbridger, Laura H Porter, Mitchell G. Lawrence
Publikováno v:
The Journal of Pathology. 254:121-134
Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent studies highlighted that these amplifications not only span the AR gene but usually encompass a distal enhancer. This repr
Autor:
Rosalia Quezada Urban, Shivakumar Keerthikumar, Ashlee K. Clark, Laura H. Porter, Mitchell G. Lawrence, Renea A. Taylor, Gail P. Risbridger, Roxanne Toivanen, David L. Goode
Publikováno v:
Cancer Research. 82:4076-4076
Neuroendocrine prostate cancer (NEPC) represent an aggressive malignancy that results in poor patients outcomes. At a histological level, NEPC exhibits heterogeneous pathologies; nevertheless, the molecular features, drivers and therapeutic implicati
Autor:
Adrienne R. Hanson, Renea A. Taylor, Andrew Ryan, Mark Frydenberg, Richard J. Rebello, Elena Castro, Christine Henzler, Ross D. Hannan, Shivakumar Keerthikumar, Shelley Lee Hedwards, John Pedersen, David L Goode, Damien M Bolton, Stephen Q. Wong, Rendong Yang, Jeremy Grummet, Sam Norden, Shomik Sengupta, Richard B. Pearson, John Kourambas, Nathan Lawrentschuk, Alisée V. Huglo, Declan G. Murphy, Roxanne Toivanen, Laura H Porter, Daisuke Obinata, Jeremy Goad, Gail P. Risbridger, Mitchell G. Lawrence, Luke A. Selth, Yingming Li, Fernando López-Campos, David Clouston, Jenna Van Gramberg, Shahneen Sandhu, Arun Azad, Ashlee K. Clark, Laurence Harewood, Daniel Moon, Patricia Banks, Luc Furic, Birunthi Niranjan, Hong Wang, Natalie Lister, David Pook, Ross Snow, Scott M. Dehm, Wayne D. Tilley, Heather Thorne, Melissa Papargiris, Carmel Pezaro, Catherine Mitchell
Publikováno v:
European Urology. 74:562-572
Background The intractability of castration-resistant prostate cancer (CRPC) is exacerbated by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis and AR-independent phenotypes. The availability of additional models
Autor:
Joseph A. Trapani, Gail P. Risbridger, Michael S Hofman, Paul J Neeson, Phil Darcy, Renea A. Taylor, David J Byrne, Ian Vela, Arun Azad, Laura H Porter, Joe Zhu, Natalie Lister
Publikováno v:
Journal of the Endocrine Society
Chimeric antigen receptor T (CAR T) cell therapy is an adoptive immunotherapy that has led to new treatments for lymphoma, leukemia, and other blood cancers; however, its efficacy for prostate cancer remains unproven. Here we report pre-clinical evid
Autor:
Gail P. Risbridger, Carmel Pezaro, Ross D. Hannan, Renea A. Taylor, David L Goode, Jeremy Grummet, Nicholas Choo, David Pook, Susanne Ramm, Andrew Bakshi, Richard B. Pearson, Kaylene J. Simpson, Jennii Luu, Mitchell G. Lawrence, Shahneen Sandhu, Luc Furic, Laura H Porter, Elaine Sanij
Publikováno v:
Molecular cancer therapeutics. 20(11)
Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments are required for the remaining tumors, and an emerging strategy is to c
Autor:
Laura H Porter, David Clouston, Mitchell G. Lawrence, Mark Frydenberg, Declan G. Murphy, Gail P. Risbridger, Renea A. Taylor
Publikováno v:
Science Translational Medicine. 12
Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma